188 related articles for article (PubMed ID: 38102213)
1. Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
El Warrak S; Kharfan-Dabaja MA; Iqbal M; Hamadani M; Chavez J; Mohty R
Bone Marrow Transplant; 2024 Feb; 59(2):162-170. PubMed ID: 38102213
[TBL] [Abstract][Full Text] [Related]
2. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
3. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Zurko J; Ramdial J; Shadman M; Ahmed S; Szabo A; Iovino L; Tomas AA; Sauter C; Perales MA; Shah NN; Acharya UH; Jacobson C; Soiffer RJ; Wang T; Komanduri KV; Jaglowski S; Kittai AS; Denlinger N; Iqbal M; Kharfan-Dabaja MA; Ayala E; Chavez J; Jain M; Locke FL; Samara Y; Budde LE; Mei MG; Pia AD; Feldman T; Ahmed N; Jacobs R; Ghosh N; Dholaria B; Oluwole OO; Hess B; Hassan A; Kenkre VP; Reagan P; Awan F; Nieto Y; Hamadani M; Herrera AF
Haematologica; 2023 Jan; 108(1):98-109. PubMed ID: 35833303
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
11. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Gupta S; Kohorst M; Alkhateeb HB
Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
13. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P; Bethge WA; Krämer I; Holtick U; von Tresckow B; Ayuk F; Penack O; Vucinic V; von Bonin M; Baldus C; Mougiakakos D; Wulf G; Schnetzke U; Stelljes M; Fante M; Schroers R; Kroeger N; Dreger P;
Transplant Cell Ther; 2023 Dec; 29(12):750-756. PubMed ID: 37709204
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
16. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
18. Bispecific CAR T-cells for B-cell Malignancies.
Furqan F; Shah NN
Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
[TBL] [Abstract][Full Text] [Related]
19. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
20. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Chong EA; Alanio C; Svoboda J; Nasta SD; Landsburg DJ; Lacey SF; Ruella M; Bhattacharyya S; Wherry EJ; Schuster SJ
Blood; 2022 Feb; 139(7):1026-1038. PubMed ID: 34496014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
